Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
She writes for both print and online media, and has written for HealthDa
Retatrutide (LY3437943) is a single peptide engineered to agonise three incretin-family receptors at once: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR) 26
Together, these peptides create combined effects that clinical trials show can produce up to 25% total body weight reduction, greatly exceeding what either peptide achieves independently and surpassing all other now available weight loss drugs
BMJ , 384
Retatrutide: Early research suggests up to 2024% weight loss in some participants, making it one of the most promising emerging medications
